- Home
- SRE vs REGN Comparison
SRE vs REGN Comparison
Compare SRE & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRE
- REGN
- Stock Information
- Founded
- SRE 1998
- REGN 1988
- Country
- SRE United States
- REGN United States
- Employees
- SRE N/A
- REGN N/A
- Industry
- SRE Oil/Gas Transmission
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- SRE Utilities
- REGN Health Care
- Exchange
- SRE Nasdaq
- REGN Nasdaq
- Market Cap
- SRE 60.3B
- REGN 59.5B
- IPO Year
- SRE N/A
- REGN 1991
- Fundamental
- Price
- SRE $93.02
- REGN $649.56
- Analyst Decision
- SRE Buy
- REGN Buy
- Analyst Count
- SRE 13
- REGN 21
- Target Price
- SRE $92.08
- REGN $779.00
- AVG Volume (30 Days)
- SRE 3.0M
- REGN 1.0M
- Earning Date
- SRE 11-05-2025
- REGN 10-28-2025
- Dividend Yield
- SRE 2.79%
- REGN 0.55%
- EPS Growth
- SRE N/A
- REGN 2.88
- EPS
- SRE 3.25
- REGN 41.59
- Revenue
- SRE $13,711,000,000.00
- REGN $14,247,800,000.00
- Revenue This Year
- SRE $7.18
- REGN $1.34
- Revenue Next Year
- SRE $4.10
- REGN $5.23
- P/E Ratio
- SRE $28.46
- REGN $15.49
- Revenue Growth
- SRE 6.14
- REGN 2.89
- 52 Week Low
- SRE $61.90
- REGN $476.49
- 52 Week High
- SRE $95.77
- REGN $844.51
- Technical
- Relative Strength Index (RSI)
- SRE 62.42
- REGN 66.46
- Support Level
- SRE $90.84
- REGN $625.14
- Resistance Level
- SRE $94.75
- REGN $664.00
- Average True Range (ATR)
- SRE 1.69
- REGN 17.53
- MACD
- SRE -0.25
- REGN 4.64
- Stochastic Oscillator
- SRE 67.74
- REGN 84.17
About SRE DBA Sempra
Sempra Energy serves one of the largest utility customer bases in the United States. It distributes natural gas and electricity in Southern California and owns 80% of Oncor, a transmission and distribution business in Texas. Sempra Infrastructure partners, of which Sempra will hold a 25% ownership, owns and operates liquefied natural gas facilities in North America and infrastructure in Mexico.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).